Specific serologic response to genital human papillomavirus types in patients with vulvar precancerous and cancerous lesions

Heim, K.; Widschwendter, Andreas; Szedenik, Hannes; Geier, Andrea; Christensen, Neil D.; Bergant, A.; Concin, Nicole; Höpfl, Reinhard

doi:10.1016/j.ajog.2004.09.130

Cited by 12 publications

(13 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[28][29][30][31][32] Several studies have shown that infection with HPVs leads to synthesis of type-specific and neutralizing antibodies against viral epitopes in adults. 4,[6][7][8][10][11][12][13]27,33 Although reports indicate that a high HPV prevalence in Results provided some evidence that vertical HPV transmission from mother to child followed by antibody production can occur but is rare. Kawana et al 30 demonstrated the neutralizing capacity of maternal and newborn HPV-6 IgG positive sera in 2 cases in which maternal condylomata occurred during pregnancy.…”

Section: Discussionmentioning

confidence: 92%

Type-Specific Antiviral Antibodies to Genital Human Papillomavirus Types in Mothers and Newborns

Heim

Hudelist²,

Geier

et al. 2007

Reprod. Sci.

Self Cite

View full text Add to dashboard Cite

Type-specific antibodies to human papillomaviruses (HPVs) can be detected in most infected adult patients, and they have virus-neutralizing properties. However, there is a dearth of information on the seroprevalence of maternal and neonatal antibodies to HPV capsid antigens. Sera from 104 mothers, their newborns, and 3 twin pregnancies were analyzed by an enzyme-linked immunosorbent assay (ELISA) for the presence of specific IgG, IgM, and IgA antibodies to virus-like particles of HPV-6, -11, -16, -18, and -31. Maternal IgG positivity rates to HPV types 6, 11, 16, 18, and 31 were 23.1%, 2.9%, 8.7%, 5.8%, and 9.6%, respectively. Neonatal rates did not differ significantly, and individual IgG ELISA values of mothers and their infants and all paired twins showed a very high correlation. In contrast, nearly all IgM and IgA individual values in newborns were designated negative, whereas mothers' positivity rates ranged as high as 19.2%. Infants showed no HPV-related lesions at birth or at 4-year follow-up. Seven of 8 tested children lost IgG HPV antibodies in a follow-up examination. Similar anti-HPV IgG seropositivity in mothers and newborns and a lack of neonatal IgA and IgM together with twin and follow-up results indicate that neonatal IgG is not a sign of intrauterine HPV infection but, rather, maternofetal antibody transmission.

show abstract

Section: Discussionmentioning

confidence: 92%

Type-Specific Antiviral Antibodies to Genital Human Papillomavirus Types in Mothers and Newborns

Heim

Hudelist²,

Geier

et al. 2007

Reprod. Sci.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Data from Western Europe were available from Austria (42-45), Finland (46-51), Germany (52-54), Italy (40,55), The Netherlands (10,40,56), Norway (57,58), Spain (16,59), Sweden (60-69) and the United Kingdom (70,71). The only studies from Eastern Europe were from the Czech Republic (72-74).…”

Section: Resultsmentioning

confidence: 99%

Age-Specific Human Papillomavirus Antibody and Deoxyribonucleic Acid Prevalence: A Global Review

Tiggelaar¹,

Lin²,

Viscidi³

et al. 2012

Journal of Adolescent Health

View full text Add to dashboard Cite

Purpose Global data on human papillomavirus serological and DNA prevalence are essential to optimize HPV prophylactic vaccination strategies. Methods We conducted a global review of age-specific HPV antibody and studies with both antibody and DNA prevalence for HPV types 16, 18, 6 and 11. Results One hundred-seventeen studies were included; participants’ ages ranged from several hours to over 90 years. HPV 16 seroprevalence was generally higher in Africa, Central and South America, and North America, more prevalent among women than men, and peaked around ages 25-40 years. HPV 18 seroprevalence was generally lower than HPV 16 with a later age peak. Data were limited for HPV 6 and 11, which both peaked at ages similar to HPV 18. In 9-26 year-old females, HPV 16 seroprevalence ranged from 0-31% in North America, 21-30% in Africa, 0-23% in Asia/Australia, 0-33% in Europe, and 13-43% in Central and South America. HPV 16/18 DNA prevalence peaked 10-15 years before corresponding HPV 16/18 antibody prevalence. Conclusions Females within the HPV-vaccine eligible age group (9-26 years) had a range of dual HPV 16 DNA and serology negativity from 81-87%, whereas 90-98% were HPV 16 DNA negative. Serology and DNA data are lacking worldwide for females younger than age 15 years, the prime target group for vaccination.

show abstract

“…Recently, Heim et al (2005) have proposed an explanation of the observed correlation between prognosis and HPV serostatus. In high-grade CIN, a subset of lesions can be identified in which the viral genome has integrated and there is a greater risk of malignant progression (Pirami et al, 1997).…”

Section: Discussionmentioning

confidence: 98%

Serologic response to human papillomavirus type 16 virus-like particles in Korean women with cervical precancerous and cancerous lesions

et al. 2009

View full text Add to dashboard Cite

The aim of the study was to investigate the seroprevalence to HPV type 16 in Korean women with precancerous and cancerous lesions of the uterine cervix. The cases were 173 Korean women of whom 130 had high-grade cervical intraepithelial neoplasias (CIN), 43 cervical carcinomas and the control group was 106 women showing normal cervical cytology. Serologic assays were performed using HPV-16 VLPs as antigen in an ELISA. Specific antibodies against HPV-16 VLP were detected in 59.2% (77/130) of the patients with high-grade CIN, in 67.4% (29/43) of the patients with cervical cancer and in 20.8% (22/106) of control subjects. No difference of serologic response was found between high-grade CIN and cancer. HPV-16 seropositivity showed the significant association with patients' age and preoperative HPV DNA infection. Recurrence of high-grade CIN was not affected by the VLP-16 seropositivity. Recurrence of carcinoma showed the borderline association with HPV-16 seropositivity (P=0.06). The association between the cancer recurrence and seropositivity was not found in the logistic regression analysis. Two patients dying of cancer during the follow-up period were both seronegative (P=0.01). In conclusion, serologic testing for HPV-16 VLP antibody provides a disease indicator of cervical lesions and potential prognostic parameter of cervical carcinoma.

show abstract

Specific serologic response to genital human papillomavirus types in patients with vulvar precancerous and cancerous lesions

Cited by 12 publications

References 22 publications

Type-Specific Antiviral Antibodies to Genital Human Papillomavirus Types in Mothers and Newborns

Type-Specific Antiviral Antibodies to Genital Human Papillomavirus Types in Mothers and Newborns

Age-Specific Human Papillomavirus Antibody and Deoxyribonucleic Acid Prevalence: A Global Review

Serologic response to human papillomavirus type 16 virus-like particles in Korean women with cervical precancerous and cancerous lesions

Contact Info

Product

Resources

About